The faculty of the Division of Hematology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) includes clinician, physician-scientists and basic scientists. The Division’s research focuses on discovering biologic mechanisms underlying the development of hematologic malignancies, searching for genetic and epigenetic aberrations that modify response to treatment, and developing novel drug therapies for targeting specific molecular alterations in patients with hematologic malignancies. A common goal in the Division is to move rapidly toward personalized therapy programs tailored to individual patients based on the genetic and epigenetic “make-up” of their diseases. In order to pursue this goal, basic researchers and clinicians in the Division work side-by-side to ensure that each novel discovery made in the laboratories is utilized for designing novel therapeutic strategies. Each observation made in the clinic is carefully considered to understand the basic mechanisms of hematologic malignancies at the bench.
The Division is highly recognized for its scientific achievements. Recently, the National Cancer Institute (NCI) awarded one of only two Leukemia Specialized Programs of Research Excellence (SPORE) grants to Dr. John Byrd, Division Director. Dr. Byrd was also recently awarded a prestigious Specialized Center of Research (SCOR) grant by the Leukemia & Lymphoma Society of America. Thus, the Division of Hematology is the only Division in the country to have been awarded both these grants of “excellence”. In addition, members of the Division lead phase I and phase II clinical trials for hematologic malignancies under the provisions of the U01 and N01 contracts awarded by the NCI to Dr. Michael Grever, MD and Dr. Miguel Villalona, MD, respectively. The Ohio State University is part of a very limited group of cancer institutions that have received both NCI contracts.
The Division of Hematology also participates in clinical trials and correlative science studies conducted by the Cancer and Leukemia Group B (CALGB), a multidisciplinary national cooperative clinical cancer study group funded by the NCI. Members of the Division are currently chair or members of several CALGB committees and lead CALGB clinical trials in leukemia and lymphoma.
In addition, the Division includes a superb benign hematology service led by Dr. Eric Kraut. Experts in the field provide outstanding diagnostic service, routine care and access to cutting edge clinical trials to patients with coagulation, hemoglobin and other rare hematologic disorders.
The Division integrates its large patient population, excellent clinical and basic science faculty and the superb facilities of the OSUCCC-James with pertinent disciplines such as pathology, radiation oncology, surgical oncology, gynecologic oncology and pediatric oncology to provide comprehensive clinical and research training in hematology and hematologic oncology.